T Cell News and Research

Latest T Cell News and Research

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

Researchers identify how p110delta molecule controls the body's inflammatory responses

Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism.

1 Oct 2012

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

1 Oct 2012

Common RNA pathway links frontotemporal lobar dementia with ALS

Two proteins previously found to contribute to ALS, also known as Lou Gehrig's disease, have divergent roles. But a new study, led by researchers at the Department of Cellular and Molecular Medicine at the University of California, San Diego School of Medicine, shows that a common pathway links them.

1 Oct 2012

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Exelixis, Inc. today reported preliminary data from an ongoing phase 1 dose escalation study of cabozantinib in Japan.

1 Oct 2012

CIB2 genetic mutation responsible for deafness associated with Usher syndrome type 1

Researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have found a new genetic mutation responsible for deafness and hearing loss associated with Usher syndrome type 1.

1 Oct 2012

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

Study finds differences and similarities between iPSCs and cancer cells

UC Davis investigators have found new evidence that a promising type of stem cell now being considered for a variety of disease therapies is very similar to the type of cells that give rise to cancer. The findings suggest that although the cells -- known as induced pluripotent stem cells (iPSCs) -- show substantial promise as a source of replacement cells and tissues to treat injuries, disease and chronic conditions, scientists and physicians must move cautiously with any clinical use because iPSCs could also cause malignant cancer.

29 Sep 2012

Sorafenib does not improve overall survival among patients with NSCLC

Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. However, a post-hoc biomarker analysis of the trial data that was also presented suggests that patients with EGFR-mutant tumors may benefit.

29 Sep 2012

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD Pharmaceuticals, Inc. today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.

29 Sep 2012

Drug combinations show promise against metastatic melanoma

Promising new data on drug combinations to treat metastatic melanoma are presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

Sensus Healthcare is pleased to announce the acceptance and publication of the most comprehensive study to date on treating Non Melanoma Skin Cancer (NMSC) with superficial radiotherapy (SRT) in the Journal of the American Academy of Dermatology (JAAD).

29 Sep 2012

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

The online journal PLOS ONE released a scientific report on the validation of Falcon Genomics' Cancer BioChip System (CBCS) as a tool for identifying inhibitors of breast cancer.

29 Sep 2012

Rapamycin can alleviate frontotemporal lobar degeneration

A southern Taiwan-based National Cheng Kung University (NCKU) research team has discovered that rapamycin, a drug as a autophagy activator is a possible treatment to alleviating frontotemporal lobar degeneration (FTLD), one of the mainly causes of dementia, and so far no medication can be used.

29 Sep 2012

GCE group, Dehaier partner to distribute EASE II products in China

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has signed a two-year distribution agreement with GCE group, a leading global compressed gas-equipment company, to become the exclusive distributor for GCE's EASE II products in Mainland China.

29 Sep 2012

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).

29 Sep 2012

BioTime forms new wholly owned subsidiary

BioTime, Inc., an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine utilizing stem cells and related technology, announced today that it has formed a new wholly owned subsidiary, BioTime Acquisition Corporation, to pursue opportunities and acquire assets and businesses in the fields of stem cells and regenerative medicine.

29 Sep 2012

Cholesterol precursor suppresses inflammatory response genes, causes atherosclerosis

Atherosclerosis - the hardening of arteries that is a primary cause of cardiovascular disease and death - has long been presumed to be the fateful consequence of complicated interactions between overabundant cholesterol and resulting inflammation in the heart and blood vessels.

28 Sep 2012

T Cell News and Research

Latest T Cell News and Research

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Researchers identify how p110delta molecule controls the body's inflammatory responses

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Common RNA pathway links frontotemporal lobar dementia with ALS

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

CIB2 genetic mutation responsible for deafness associated with Usher syndrome type 1

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Study finds differences and similarities between iPSCs and cancer cells

Sorafenib does not improve overall survival among patients with NSCLC

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

Drug combinations show promise against metastatic melanoma

Synta announces results from ganetespib Phase 2b trial on NSCLC

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

Rapamycin can alleviate frontotemporal lobar degeneration

GCE group, Dehaier partner to distribute EASE II products in China

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

BioTime forms new wholly owned subsidiary

Cholesterol precursor suppresses inflammatory response genes, causes atherosclerosis

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in